To assess whether DCLK1-mediated alteration in β-catenin correlated with clinical activity, we first analyzed the TCGA database for β-catenin mRNA expression levels in HCC, cholangiocarcinoma, and colorectal adenocarcinoma. The gene discussed is DCLK1; the disease is hepatocellular carcinoma.